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Genotype 1a is a most prevalent genotype of hepatitis C virus in North America yet HCV replication has been studied predominantly with
genotype 1b subgenomic replicons under neomycin selection in Huh-7 cells. Development of 1a-related dicistronic replicons under neo
selection proved difficult and required either bconditionedQ Huh-7 cells and/or chimeric genomes harboring pre-engineered adaptive
mutations. We report the construction of a novel dicistronic genotype 1a(H77C) replicon expressing the puromycin N-acetyltransferase
(PAC) gene as a selectable marker that, without prior introduction of adaptive mutations, allows establishment of puromycin-resistant Huh-7
colonies after transfection of naRve Huh-7 cells. The large majority of HCV1a/PAC replicons did not reveal any adaptive mutations on short-
term passage of Huh-7 cells. Continued passage led to mutations in the non-structural genes although these mutations did not significantly
enhance replication of the original replicon. Transfection with total cellular RNA isolated from HCV1a/PAC replicon-containing cells led
to a significant increase in colony-forming ability. The data identify PAC as an efficient selectable marker for studies of HCV replication,
which may be useful with different genotypes in different host cell systems.
D 2005 Elsevier Inc. All rights reserved.
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Hepatitis C virus (HCV), a human virus, causes inflam-
mation of the liver, a condition that frequently progresses to
persistent infection and very serious chronic liver disease.
With an estimated 200 million people infected worldwide,
HCV, the sole member of the genus Hepacivirus of
Flaviviridae, has emerged as a major public health problem
(Wasley and Alter, 2000). Currently, there are no specific
anti-HCV vaccines or drugs available although combination0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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USA.therapy with interferon and ribavirin has led to limited
success in viral clearance and cure (Medina et al., 2003;
Poynard et al., 1998; Reichard et al., 1998).
HCV genomes are distinct by broad sequence diversity.
They have been separated into six major genotypes of
which various combinations cluster in different parts of the
world. Genotypes 1a and 1b are the most prevalent
genotypes in North America (Zein et al., 1996). Unfortu-
nately, the success rate in treatment of genotype 1-caused
persistent infections with interferon/ribavirin is low as
compared to the treatment of persistent infections of other
genotypes (Zein, 2000). The HCV genome expresses a
polyprotein with an order of coding regions typical for
Flaviviridae (Choo et al., 1989; Reed and Rice, 2000;
Fig. 1A). The most pronounced difference between HCV
and member viruses of the genus Flavivirus (e.g., yellow005) 41–53
Fig. 1. Schematic representation of the HCV genome and the subgenomic HCV replicon HCV1a/PAC and selection of puromycin-resistant colonies.
(A) Structure of the HCV genome. The open reading frame indicated by boxes is flanked by the 5V and 3VNTR. The structural proteins are located in the NH2-
terminal part of the polyprotein (stripped boxes), and the remainder (NS2 to NS5B) encodes the nonstructural proteins. (B) Structure of the HCV1a-based
replicon designated as HCV1a/PAC. It is composed of the HCV 5VNTR (solid line), the first 11 amino acids of the core region (solid box) fused to the PAC
gene (shaded box), the EMCV-IRES (solid line), and HCV sequences from NS3 to NS5B and the 3VNTR. PAC, puromycin N-acetyltransferase. (C) Puromycin-
resistant colonies produced after transfection with wild type (wt) and mutant HCV replicon RNAs. Transfections of Huh-7 cells with the wt (Left) and NS5B
(pol) (Right) mutant replicon RNAs were carried out as described in Materials and methods.
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ribosomal entry site (IRES) in the 5V non-translated region
(NTR) (Tsukiyama-Kohara et al., 1992). There is no
evidence of a 5V-terminal capping group in viral RNA,
which may explain the adoption of an IRES by the HCV
genome. The precise nature of the 5V end in virion RNA is
still uncertain.
All HCV genotypes notoriously resist cultivation in
tissue culture. Studies of the molecular biology of viral
proliferation have, therefore, relied on subgenomic dicis-
tronic replicons (Lohmann et al., 1999), which resemble in
architecture dicistronic polioviruses and dicistronic polio-
virus expression vectors (Alexander et al., 1994; Molla et
al., 1992). In these dicistronic HCV replicons, the open
reading frame of the HCV polyprotein, or a segment thereof,
is driven by the IRES of encephalomyocarditis virus (Jang
et al., 1988), while the HCV IRES is used to drive the gene
of a selectable marker, neomycin phosphotransferase (neo)
(Lohmann et al., 1999). The neo gene confers resistance to
neomycin sulfate (G418). Interestingly, Huh-7 cells, derived
from human hepatoma, have been found to serve as the only
efficient cell line in which replication of replicons was
scored after transfection of in vitro transcribed RNA.
Following neo selection, cell colonies have been isolated,
which contained efficiently replicating dicistronic subge-
nomes. These replicon RNAs revealed distinct adaptivemutations, mapping to different coding regions of the
polyprotein (Blight et al., 2000; Lohmann et al., 2001;
Guo et al., 2001; Krieger et al., 2001). Interestingly,
adaptive mutations rapidly evolved in HCV[Con1] rep-
licons (Con1 referring to the 1b HCV strain from which
the replicon was constructed) and were found to be required
for efficient replication. In contrast, replicons based on
different strains of genotype 1b, e.g., HCV-N (Ikeda et al.,
2002) or genotype 2a JFH-1 (Kato et al., 2003), did not
display such degree of needed genetic variation for survival
in neomycin-treated cells. This is surprising and indicates
some degree of genotype-related dependence of neo-
selected replicons.
Recently, the host range for HCV dicistronic replicons has
been expanded to human HeLa cells (derived from a human
cervical carcinoma) and mouse hepatoma cells (Zhu et al.,
2003). However, cell colonies under neomycin selection
could not be established when transcript RNAs were
transfected into these cells (Zhu et al., 2003). It was necess-
ary to use total RNA of replicon-carrying cells for trans-
fections. This interesting restriction will be discussed later.
So far, all HCV replicons are based on selection to
neomycin resistance, and by far the largest number of
studies has been carried out with subgenomic RNA of
the 1b genotype. For unknown reasons, constructs with
the genotype 1a sequence, nearly identical in architecture
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that would support replication under neomycin selection.
Nonetheless, specific cell lines harboring 1a-specific repli-
cons under neomycin selection have been developed
recently (Blight et al., 2003; Grobler et al., 2003). However,
the cells used to establish persistent replication of 1a
replicons were not bnaRveQ Huh-7 cells but Huh-7 cells that
had been bcuredQ previously from 1b HCV replicons with
interferon (Blight et al., 2002; Murray et al., 2003). The
phenotype of the more permissive cells, referred to by
Blight et al. (2002) as Huh-7.5 cells, is not well understood,
but the previous presence of replicating HCV replicons must
have left persistent imprints to render the cells more
accommodating for uptake, translation, or RNA synthesis
of the HCV replicons.
Gu et al. (2003) and Yi and Lemon (2004) have also
succeeded recently in the construction of 1a replicons
supporting the establishment of naRve Huh-7 cells under
neo selection. However, these 1a replicons are chimeras in
which the 5V-terminal 225 nt of the NS3 reading frame of 1a
was replaced with those of genotype 1b to facilitate better
translation of the 1a-specific ORF (Guo et al., 2001).
Moreover, replication of these chimeric 1a replicons in
naRve Huh-7 cells was achieved only if a mutation (S2204I),
known previously from studies with 1b replicons to greatly
enhance replication, was engineered into the 1a NS5A
coding sequence (Gu et al., 2003; Yi and Lemon, 2004).
In pursuit of an alternative model system for HCV
replicons, we describe here the development of a dicistronic
replicon expressing the puromycin N-acetyltransferase
(PAC) gene, a selectable marker conferring puromycin
resistance to transfected cells. As the model HCV RNA, we
chose genotype 1a [H77C] HCV the genome of which had
been cloned previously by Yanagi et al. (1997). Puromycin-
resistant colonies were easily recovered after transfection of
naRve Huh-7 cells under appropriate conditions and repli-
cation of HCV1a/PAC replicon RNAwas observedwith ~500
copies per cell. Establishment of cells harboring the
HCV1a/PAC replicon under puromycin selection did not
require prior mutation of the HCV genome. A high
percentage of clonal Huh-7 cell lines were able to support
HCV replication under puromycin selection independent
of adaptive mutations in the replicons. On long-term
passage of Huh-7 cells harboring 1a/PAC replicon RNA
under continuous selection revealed, depending upon the
clone selected for analyses, some mutations of which
the S2204I mutation in NS5A dominated. However, in
vitro reconstructed mutant replicon RNA harboring the
S2204I mutation had only a modest effect on the initia-
tion of RNA replication whereas transfection with total
cellular RNA isolated from genotype 1a replicon contain-
ing naRve cells led to a significant increase in the number
of resistant colonies.
The data show that a dicistronic replicon expressing the
PAC selectable marker offers an attractive new avenue for
the study of HCV genotypes other than genotype 1b.Results
An HCV1a/PAC replicon conferring puromycin resistance
to naı¨ve Huh-7 cells
The difficulties of transferring the strategy of dicistronic
1b replicons expressing the neo gene in Huh-7 cells (Blight
et al., 2000; Ikeda et al., 2002; Kato et al., 2003; Lohmann
et al., 1999, 2001) to the equivalent 1a genotype (Blight et
al., 2000; Guo et al., 2001; Ikeda et al., 2002) are
unexplained. It could be due to the intrinsic properties of
proteins expressed by HCV 1a in combination with
neomycin selection in Huh-7 cells. Whatever the reason,
the restriction has been overcome recently by, first, using
either bcuredQ Huh-7 cells (Blight et al., 2002; Murray et al.,
2003) that were permissive to replication of 1a replicons
under neomycin selection (Blight et al., 2003; Grobler et al.,
2003) or, second, by using 1a/1b chimera harboring an
engineered mutation in the coding region of NS5A (Gu et
al., 2003; Yi and Lemon, 2004). These modified chimeric
replicons allowed replication in naRve Huh-7 cells.
We have explored the possibility whether a different
model of selection in Huh-7 cells may favor the establish-
ment of cell lines harboring efficiently replicating 1a-related
dicistronic replicons. We speculated that the neo selection
might block in some manner the establishment of stable cell
lines when naRve Huh-7 cells or when the unchanged 1a
genotype is used. Therefore, we constructed a dicistronic
replicon similar to that originally described by Lohmann
et al. (1999) except that the neo resistance gene was re-
placed by a gene encoding puromycin N-acetyltransferase
(PAC). Expression of the small PAC gene (597 bp) in
transfected cells confers resistance to puromycin, a potent
inhibitor of translation. PAC has been used successfully in
alphavirus replicons for the selection of specific alphavirus
phenotypes (Frolov et al., 1999). We speculated that a
transdominant marker different from neomycin might allow
the 1a-specific replicon to establish cell colonies under
puromycin selection.
The HCV1a/PAC replicon used in our studies is based on
the infectious HCV 1a-cDNA clone H77C, originally
constructed by Yanagi et al. (1997) (Fig. 1A). The genetic
map of the HCV1a/PAC replicon, [HCV]5VNTR-Dcore-
PAC-[EMCV]IRES-[HCV]NS3-NS4-NS5-3VNTR (Fig. 1B),
entails the HCV 5V NTR including the IRES that regulates
the synthesis of PAC, and the EMCV IRES regulating the
expression of the truncated 1a HCV polyprotein. The gene
for PAC has been fused at the 5V end to a small segment of
the core protein reading frame (33 nt) since a nucleotide
sequence downstream of the initiating AUG is required for
HCV IRES-mediated translation (Lu and Wimmer, 1996;
Reynolds et al., 1995). The NS3 to NS5 coding regions
specify proteins absolutely essential for replicon replication
(Bartenschlager and Lohmann, 2001; Reed and Rice, 2000).
NS3 is a serine proteinase and a helicase, NS4A a co-factor
for the NS3 proteinase by forming a heterodimer, and NS5B
Fig. 2. RT-PCR analysis of the total cellular RNA from a selected Huh-7
clone. NS5B-specific primers were used for the standard RT-PCR analysis, as
described inMaterials andmethods. As control, RT-PCR reaction with naRve
Huh-7 cellular RNA, with (Lane 3) and without RNA template (Lane 2),
was included. Lanes 1 and 6: DNA molecular weight marker III (M); Lane
4: RT-PCR of the total cellular RNA from a selected Huh-7 clone; Lane 5:
RT-PCR of the respective transcript RNA (+). The resulting 1540-bp
fragment DNA was detected on an agarose gel and identified as NS5B
sequence by DNA sequencing.
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formation of cytoplasmic vesicles that are thought to
function as platform for RNA replication (Egger et al.,
2002; Hugle et al., 2001). The function(s) of NS5A, a highly
phosphorylated protein, is not yet known. Recently, it has
been reported that hyper-phosphorylation of NS5A can
down-regulate HCV RNA replication in cell culture
(Neddermann et al., 2004).
Huh-7 cells, which allow replication of HCV 1b/neo
replicon RNA, were also chosen for transfections with the
1a-specific replicons. Run-off transcripts of the HCV1a/
PAC replicon plasmid (see Materials and methods) were
introduced into naRve Huh-7 cells, and the transfected cells
were grown under the selection of puromycin. As reported
previously, 1a replicons expressing neomycin resistance
failed to yield colonies under neomycin selection in similar
experiments (Blight et al., 2000; Guo et al., 2001).
However, transfection of HCV1a/PAC replicon RNA
followed by selection resulted reproducibly in puromycin-
resistant colonies, ranging from 20 to 200 colonies per
microgram of RNA (Fig. 1C). A mutant construct carrying a
NS5B RNA polymerase-defective lethal mutation failed to
produce colonies, as expected (Fig. 1C). Transfection
efficiency was affected by the condition of cell growth:
80–85% subconfluent Huh-7 cells passaged at regular
intervals were optimal for RNA transfection. The relative
efficiency of transfection was consistent across different
samples. No obvious changes in cell morphology were
observed in isolated colonies except a slight retardation of
growth in comparison with naRve Huh-7 cells. All selected
cell lines displayed persistent resistance to puromycin in the
medium at 2–4 Ag/ml. These results suggest that PAC
selection can be used to isolate colonies harboring replicat-
ing 1a-dicistronic replicons.
Multiple independent clonal Huh-7 cell lines supporting
HCV1a/PAC subgenomic RNA replication post transfec-
tion, as well as a cell line derived from pooled puromycin-
resistant colonies post-selection, were examined and
showed similar replication profiles (data now shown). Data
presented in the following for RNA and protein analyses
have been derived from the fastest growing clone, clone A.
Evidence of viral RNA replication and viral protein
expression in Huh-7 cells transfected with
HCV1a/PAC replicon transcripts
The presence of replicon RNA in puromycin-resistant
Huh-7 cells (clone A) after the first few consecutive
passages was analyzed by RT-PCR with HCV-specific
primers (see Materials and methods). An RT-PCR fragment
of the expected size was generated from RNA of the
transformed cells (Fig. 2). There was no amplification of
DNA fragments that may have resulted from carry-over of
plasmid DNA or from integration of plasmid DNA because
direct PCR assay of total cellular DNA with viral-specific
or PAC-specific primers, bypassing the step of reversetranscription, did not yield any positive PCR products (data
not shown).
Replication of 1a-specific replicon RNA was then
demonstrated by metabolic labeling with [3H]-uridine in
the presence of 5 Ag/ml actinomycin D (ActD), a potent
inhibitor of cellular DNA-dependent RNA synthesis at this
concentration. This method has been previously applied for
1b replicons (Lohmann et al., 1999). Clone A cells (106)
harboring the HCV1a/PAC replicon and the same number of
naRve Huh-7 cells were preincubated with actinomycin D for
1 h after which [3H]-uridine was added (see Materials and
methods). Fig. 3A shows that the level of labeled RNA in
clone A cells increased more than 10-fold during the first 30
h of incubation, then dropped sharply. No labeling of
cellular RNA was observed under the same conditions, a
result strongly suggesting that the labeled RNA corre-
sponded to replicon RNA. Indeed, autoradiography of total
RNA revealed a band with the estimated molecular weight
(~7.8 kb) expected for a 1a replicon RNA (data not shown).
The loss of [3H]-uridine-labeled RNA after 30 h is most
likely due to degradation under the condition of Act D-
induced host cell death.
In further support that replicon RNA of correct size was
present in persistently selected clone A cells, total cellular
RNAwas isolated from 106 cells and examined by Northern
blot analysis. As shown in Fig. 3B, a band approximating
7.8 kb was observed, corresponding to the molecular weight
of intact subgenomic RNA. This is in agreement with the
result of RNA labeled metabolically with [3H]-uridine in the
presence of actinomycin D. Control samples involving naRve
Huh-7 cells did not reveal any RNA corresponding to
replicon RNA.
Using two specific monoclonal antibodies for Western
blot analyses, it was subsequently shown that the cells
transfected with clone A contained viral polypeptides NS3
and NS5B, as would be expected if the replicons proliferate
and express their encoded proteins (Fig. 4A). A rough
Fig. 3. Replication of HCV1a/PAC subgenomic replicon in Huh-7 cells. (A) In vivo [3H]-labeling of HCV-specific RNA. (a) A series of 6-cm cultured naı¨ve
Huh-7 cells and HCV1a/PAC-containing Huh-7 cells were preincubated with 5 Ag/ml actinomycin D for 1 h before the addition of [H3]-uridine (50 ACi/ml).
The plates were incubated for various times as indicated on the figure. Total cellular RNAs were extracted and the amount of [H3]-labeled RNAwas measured
by scintillation counting (Materials and methods). (b) CPM of RNA in replicon-containing Huh7 cells was corrected by subtraction of the CPM in naive Huh-7
and converted to the percentage of the maximal number of CPM. (B) Northern blot analysis of total RNA extracted from HCV1a/PAC replicon containing
Clone A cells. Total RNA (5 Ag; lane 2) was resolved in a denaturing formaldehyde agarose gel and hybridized with an HCV-specific DIG-labeled IRES probe.
Lane 1 is control of in vitro synthesized replicon RNA (equivalent to 109 copies of HCV genome). Lane 3 is total RNA isolated from naive Huh-7 cells.
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transfected cells by indirect immunofluorescence then
revealed a cytoplasmic location for NS3 (Fig. 4B, panels
b and c) and for NS5B (Fig. 4B, panels e and f). There was
no viral protein detectable in naRve Huh-7 cells (Fig. 4B,
panels a and d). These expression patterns of the viral
enzymes NS3 and NS5B resemble those observed in 1b neo/
replicons (Lohmann et al., 1999; Pietschmann et al., 2001).
These combined data allow us to conclude that a 1a
subgenomic PAC/replicon, based on the infectious HCV
1a[H77C] cDNA clone (Yanagi et al., 1997), can replicate
in Huh-7 cells and establish stable cell lines under puro-
mycin selection.
Establishment of puromycin-resistant Huh-7 cell colonies is
not dependent upon adaptive mutations in the HCV1a/PAC
replicon
Adaptive mutations are a hallmark of the genetics of
dicistronic 1b[Con1] replicons proliferating in Huh-7 cells.
They are naturally selected among the quasi species of the
replicating RNAs because they confer vastly better prolife-
ration properties to the replicon within transfected Huh-7
cells and, thus, better resistance of the host cells to the
selecting drug. The significance of adaptive mutations hasbeen recognized originally by Blight et al. (2000) and have
now been found in nearly all dicistronic HCV replicon
systems (Blight et al., 2000, 2002, 2003; Grobler et al.,
2003; Guo et al., 2001; Krieger et al., 2001; Lohmann et al.,
2001, 2003; Yi and Lemon, 2004). Adaptive mutations can
map to any coding region of the NS polyprotein, but there is
a distinct hierarchy in the effect they exert, singly or in
combination, on replication (Lohmann et al., 2003 and
references therein).
Not all replicons constructed from naturally occurring
genotypes seem to need adaptive mutations for efficient
replication. For example, the genotype 1b HCV-N replicon
did not seem to depend on adaptive mutations for efficient
proliferation in the selection of stable neo-resistant Huh-7
cells lines. However, the HCV-N replicon was peculiar in
that it revealed a four amino acid insertion in the reading
fame of NS5A (Ikeda et al., 2002), which appeared respon-
sible for the phenotype. On the other hand, a wild-type
genotype 2a replicon, constructed to express the neomycin
resistant marker, revealed high colony forming efficiency
without carrying adaptive mutations (Kato et al., 2003).
To address whether autonomous replication of HCV1a/
PAC replicon required adaptive mutations for initial
replication in clonal cell lines, nearly full-length replicon
RNAs of clone A cells were amplified by RT-PCR using
Fig. 4. Viral protein expression in 1a replicon-containing cells. (A) Western blot analysis of cytoplasmic extracts from naRve and replicon-containing Huh-7
cells. Western blot analysis was carried out as described in Materials and methods with monoclonal antibodies to NS3 or NS5B. (a) Antibody to NS3 used for
probing. Lane 1: naRve Huh-7 cells; Lane 2: replicon containing cells. (b) Antibody to NS5B used for probing. Lane 1: naRve Huh-7 cells; Lane 2: replicon
containing cells; Lane 3: purified NS5B. (B) Immunofluorescence assay of naRve Huh-7 cells and cells containing HCV1a/PAC replicons. Immunofluorescence
analysis was carried out as described in Materials and methods using either NS3 (a–c) or NS5B (d–f) specific monoclonal antibodies. NaRve Huh-7 cells (a and
d); replicon-containing cells (b, c, e, and f).
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9580). The amplicon was then directly sequenced. Notably,
except for a hitherto unnoticed change of five bases in the
NS3 reading frame of the original genotype of the HCV1a/
PAC replicon (see below), no mutations were observed in
this viral RNA population in Clone A after 2-month passage
(~20 passages). These sequence analyses were performed
on RT-PCR-amplified products derived from bulk RNA
of collected cells. Thus, mutations in individual RNA
species would have escaped detection unless a dominant
mutation, for example, S2204I in NS5A, was required so
that the HCV1a/PAC replicon could form Huh-7 colonies
after transfection. However, such a dominant mutation
was not found. Indeed, an analysis of replicon RNAs
present in puromycin-resistant cells derived from pooled
colonies did not reveal any dominant nucleotide changes.
These data strongly suggest, but do not prove, that the
selection of puromycin-resistant colonies did not depend on
a dominant mutant genotype within the population of
replicating RNAs.
If adaptive mutations were required to establish repli-
cation of HCV1a/PAC replicons in Huh-7 cells at a level
sufficient for conferring continuous drug resistance, they
should have evolved in most of the clones during earlyselection. This was, however, not the case for the majority
of the HCV1a/PAC replicons in Huh-7 cells as demon-
strated in analyses of the pooled Huh-7 cell population. To
further address this issue, the NS3-5B coding region was
amplified by RT-PCR from total cellular RNA isolated
from 12 additional independent puromycin-resistant clones
selected after 10 passages (termed clones No. 1 to 12).
Individual RNAs of clones 1 to 12 were then sequenced
(Table 1). Significantly, no mutations in the RNA and,
hence, no amino acid changes were identified in ten of the
twelve (~83%) replicons. Clone No. 12 contained a mixture
of replicons encoding both serine (S) and isoleucine (I) at
position 2204, an observation indicating that some repli-
cons in this cell line had acquired the adaptive mutation
S2204I. Replicon RNA of clone No. 6 showed the mutation
S2204I and one silent A to G change at position 6791
within NS5A. No other mutations were identified.
These data show that the establishment of puromycin-
resistant Huh-7 cells upon transfection with an HCV1a/PAC
replicon is not dependent upon adaptive mutations in the
HCV coding region. However, a S2204I mutation does
evolve in a minority of clones. The significance of this
mutation on the transduction efficiency will be analyzed
further below.
Table 1
12 independent Huh-7 cell clones tested in this study
Cell clone Nucleotide changea Amino acid changeb
1 – –
2 – –
3 – –
4 – –
5 – –
6 G6952T S2204I
A6791G Silent
7 – –
8 – –
9 – –
10 – –
11 – –
12 6952G/Tc 2204S/Id
a Numbers refer to the nucleotide position of HCV type 1a isolate H77C
(NCBI accession no. AF011751).
b Numbering of amino acids starts from the beginning of the
HCV polyprotein.
c Both G and T at position 6952 in nucleotide sequence were present in
replicon RNA population of clone 12.
d Both serine (S) and isoleucine (I) at amino acid position 2204 were
present in replicon RNA population of clone 12 (Table 2).
Table 2
Conserved mutations in HCV1a/PAC replicon (in Clone A cell)
Protein Nucleotide change a Amino acid changeb
NS3 G3434C Silent(30/30)c
G4347A A1336T (30/30)c
G4522A C1394Y (30/30)c
G4721A Silent (30/30)c
A4791G R1484G (30/30)c
A3754G D1138G (3/30)
G5049A A1570I (4/30)
NS5A A6454G H2038R (8/37)
T6930C, T6932G S2197P (4/37)
G6952T S2204I (24/37)
NS5B A8835G I2832V (3/37)
T8958C S2873P (3/37)
G9185T Silent (5/37)
a Numbers refer to the nucleotide position of HCV type 1a isolate H77C
(NCBI accession no. AF011751).
b Numbering of amino acids starts from the beginning of the
HCV polyprotein.
c Mutations already present in the original pHCV1a/PAC plasmid.
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cells after serial passage for 18 months under puromycin
selection to determine whether dominant mutations emerged
under conditions of long-term cultivation. Total RNA from
clone A cells was amplified by long distance RT-PCR,
producing two fragments spanning almost the complete
genome of replicon RNA (see Materials and methods).
These segments were then subcloned into the pGEM-T
vector for clonal sequencing. The major mutations found in
30 individual clones spanning the left half (nt 59–4654) and
37 individual clones spanning the right half of the replicon
(nucleotides 4229–7747) are summarized in Table 2.
Whereas mutations in NS4A and NS4B were not detected,
mutations were scored in NS3, NS5A, and NS5B. Twenty-
four out of 37 clones (65%) sequenced contained mutation
G6952T, resulting in an amino acid substitution S2204I in
NS5A, a genetic change that has been identified in many 1b/
neo replicons passaged in Huh-7 cells (see Bartenschlager
and Lohmann, 2001; Blight et al., 2000; Lohmann et al.,
2003; and references therein). As mentioned before, the
S2204I change in NS5Awas a mutation that was engineered
into the chimeric 1a/neo replicon and found necessary to
facilitate initiation of colony formation in Huh-7 cells (Yi
and Lemon, 2004). The S2197P mutation was found by
Krieger et al. (2001) to greatly facilitate the replication of
the HCV[Con 1] replicons of the 1b genotype but here it
was found in only 4/37 clones of continuously passaged
cells harboring the HCV1a/PAC replicon. Except for the
S2204I and S2197P mutations, other mutations listed in
Table 2 are rare or have not been reported before to occur in
efficiently replicating 1b/neo or 1a/neo replicons.
As can be seen in Table 2, all clones that we have
sequenced revealed five nucleotides in NS3 that are invariance to that of the published genotype 1a[H77C] sequence
(Yanagi et al., 1997; NCBI accession no. AF011751). Two of
these are silent mutations whereas three result in amino acid
substitutions (A1336T, C1394Y, and R1484G). These
mutations, the origin of which is obscure, are not adaptive
mutations that evolved during the cellular passages as they
were, surprisingly, present also in our original HCV1a/PAC
replicon. Currently, we have no explanation at what stage
of the construction of the HCV1a/PAC replicon these
deviations from the original 1a(H77C) sequence evolved.
Modeling of the NS3 polypeptide indicated that the three
amino acids, which differ from the published sequence of
NS3, are not located at the surface of NS3 (data not shown).
It is unlikely, therefore, that these substitutions alter
significantly the function of NS3. Nevertheless, by whatever
mechanism, they could be a factor in the HCV1a/PAC
replicon’s ability to establish stably transformed colonies in
naRve Huh-7 cells under puromycin selection. To test this
hypothesis, we analyzed the effect of back mutations of the
amino acid substitutions in NS3. Each of the residues in
the NS3 region was individually reverted to the residues
reported in the published sequence of 1a(H77C). None of
the back mutations exerted beneficial effect on RNA
replication as measured by the colony forming efficiency
(data not shown). We then analyzed whether a combination
of all three back mutations influenced the colony forming
phenotype. Again, no effect was seen (data not shown). The
sequence variation relative to 1a(H77C), which we have
found in NS3 of our HCV1a/PAC replicon, therefore, is
unrelated to the efficient replication of this replicon in naRve
Huh-7 cells.
We have also tested the possibility that these mutations
in NS3 could affect the colony forming phenotype of a
1a genomic replicon whose selection was controlled by
neomycin phosphotransferase. An HCV1a/neo replicon
harboring these mutations in NS3 could not transduce the
Table 3
Quantification of replicon RNA in Huh-7 cells
Origin of replicon RNA No. of copies per cella ECFb
WTc 392 ~100
S2204Ic 537 ~300
Clone A total RNAd 746 N5000
a Number of HCV replicon RNA molecules per cell as determined by
LightCycler quantification method. Values are the mean of three in-
dependent experiments.
b Efficiency of colony formation per microgram of HCV replicon
RNA (mean values derived from six independent transformations of each
replicon RNA).
c Transfection with in vitro synthesized RNA transcripts.
d Transfection with total cellular RNA of Clone A cells.
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(data not shown).
Effect of the adaptive mutation S2204I in NS5A on
HCV1a/PAC replication
As has been pointed out before, a S2204I mutation in
NS5A seems to confer advantage to stable replication in
Huh-7 cells of many of the replicons analyzed before. The
fact that 24 of 37 HCV1a/PAC replicons in the 1a RNA
population of the Clone A harbor the same mutation and the
observation that 2 out of 12 clones have evolved this
mutation in early stages of selection suggest a replication
advantage of replicons carrying the S2204I mutation in
Huh-7 cells. To test this hypothesis, replicon HCV1a/PAC
(S2204I) was constructed, carrying an isoleucine at position
2204. On transfection, this mutant replicon HCV1a/
PAC(S2204I), however, yielded only a modest increase (2-
to 5-fold increase on average) in the number of puromycin-
resistant colonies as compared to transfection of the wild
type 1a replicon (Fig. 5; compare bar 1 with bar 2).
Quantitative analyses revealed that the level of replicon
RNA present in HCV1a/PAC(S2204I)-transfected Huh-7
cells (passage 60) was only slightly higher than that
in HCV1a/PAC-transfected Huh-7 cells (passage N 200)
(Table 3). Nevertheless, the S2204I mutation exerted a
beneficial but small effect on the replicon’s ability to
establish puromycin-resistant colonies although the increaseFig. 5. (A) Colony forming units (CFU) per microgram of HCV replicon RNA ob
Materials and methods. Bar 1: HCV1a/PAC RNA transcript; Bar 2: mutant (S2204
containing clone A cell line. (B) Transfer of puromycin resistance by transfection
isolated from replicon-containing clone A cells was transfected into naı¨ve Huh-7 ce
drug, as described in Materials and methods.was low as compared to the effect of the same mutation
in other neo/replicon systems (Blight et al., 2000, 2003; Yi
and Lemon, 2004).
Whereas the number of colonies formed per microgram
of RNA was between 100 and 300 in transfections with
HCV1a/PAC and HCV1a/PAC(S2204I) transcript RNA,
respectively, transfections with HCV replicon RNA isolated
from HCV1a/PAC clone A cells produced N5000 colonies
per microgram replicon RNA (Fig. 5A, bar 3). In view of
the quite similar levels of replicon RNAs in different cell
lines (Table 3), which corresponded to approximately 400
to 800 copies of replicon RNA per cell, this 50-fold in-
crease in colony forming efficiency is surprising. The pos-
sible reason for this phenomenon will be discussed later.tained from different sources. Transfections were carried out as described in
I) replicon RNA transcript; Bar 3: total cellular RNA isolated from replicon
of total cellular RNA containing type 1a replicon. 10 Ag total cellular RNA
lls and subjected to puromycin selection under different concentration of the
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a puromycin concentration of 2 Ag/ml. It should be noted,
however, that the transfer of puromycin resistance to Huh-7
cells occurs in a drug-dependent manner (Fig. 5B).Discussion
For reasons that cannot be explained presently, studies of
a dicistronic HCV replicon of genotype 1a, expressing a
neomycin selectable marker as described by Lohmann et al.
(2001) for HCV genotype 1b, were unsuccessful because no
stable Huh-7 cell lines could be established in the presence
of neomycin (see, for example, Blight et al., 2000). This
changed when Blight et al. (2003) and Grobler et al. (2003)
used Huh-7 cells that had been bcuredQ from previously
carrying replicating HCV replicons of genotype 1b by
treatment with interferon (Blight et al., 2002). Transfection
of these cured cells with 1a[H77C] dicistronic replicon
transcript RNAs allowed the establishment of stable cell
lines under neomycin selection, whereas transfection of
naRve Huh-7 cells with the same RNA did not (Blight et al.,
2003). The permissive phenotype of these cured Huh-7 cells
to HCV replicon replication is most interesting. It may result
from permanent genetic imprints on Huh-7 cells by previous
HCV 1b replicons that inactivated or weakened a protective
mechanism against a new transfection and neomycin
selection with replicons (Blight et al., 2002; Lohmann
et al., 2003). Alternatively, the bcuredQ cells may present a
class of highly permissive cells selected by their previous
encounter with HCV replicons (Blight et al., 2002;
Lohmann et al., 2003).
In contrast, transfection followed by drug selection with
the HCV1a[H77C]/PAC replicon described here did not
require bcuredQ Huh-7 cells. At a concentration of 2 Ag/ml in
the tissue culture media, where all naRve Huh-7 cells are
killed, we reproducibly scored 20–200 colonies. A colony
of an expanded replicon-containing cell line was stable
under drug selection for 2 years. We expected that we would
also select for replicon genotypes carrying adaptive muta-
tions conferring a highly advantageous replication pheno-
type to the HCV dicistronic RNA. This was not the case.
Except for the five nucleotide changes in the NS3 reading
frame that were present in the original replicon clone (see
below), no dominant mutations were found in replicon
RNAs isolated from cells after b20 passages. Analysis of
replicon RNAs of several independently isolated transduced
cells at b20 passages revealed that only two of thirteen
replicons harbored a sole amino acid change (S2204I) in
NS5A. However, when replicon RNA was analyzed after
N200 passages by subcloning and sequencing, mutations in
NS3, NS5A, and NS5B were found of which only the
S2204I in NS5A was frequent (24 out of 37 subclones).
The selection for the S2204I mutation in our system as a
preferred mutation in a majority of replicons occurred only
over continued passages. Transduction of naRve Huh-7 cellswith an HCV1a/PAC(S2204I) replicon into which this
mutations had been introduced prior to transfection experi-
ments did not yield a large increase in the ability of colony
formation. This strongly suggests that the S2204I mutation
is not essential in our system to establish stable Huh-7
colonies. This distinguishes the HCV1a[H77C]/PAC repli-
con from the 1a/neo replicon described by Yi and Lemon
(2004) and indicates an advantage of using puromycin
selection over neomycin selection for the HCV 1a genotype.
Although in a minority of transduced cells the S2204I
mutation evolved early in selection, our data clearly show
that the S2204I mutation is not imperative for efficient
replication of HCV1a[H77C]/PAC replicons in naRve Huh-7
cells under puromycin selection.
Transfection with total RNA from the established
HCV1a/PAC clone A yielded a significant increase in
colony formation when compared to either HCV1a/PAC
or HCV1a/PAC(S2204I) transcript RNAs. This observation
is surprising as the prominent S2204I mutation in NS5A
alone had only a very modest beneficial effect on trans-
fection with HCV1a/PAC RNA and the other mutations
were found only in a small minority of subclones (Table 2).
Zhu et al. (2003) have made a similar observation when they
studied the replication of HCV1b/neo replicons in HeLa and
mouse hepatoma cells. Indeed, transfection of HeLa cells
with replicon transcript RNAs, even if they carried the most
beneficial adaptive mutations, yielded only a few colonies
after selection whereas similar transfection of mouse
hepatoma cells yielded none (Zhu et al., 2003). Kato et al.
(2003) also observed an increase in the colony-forming
ability of RNA isolated from replicon-carrying cells. Zhu
et al. (2003) considered two possibilities to explain this
interesting phenomenon. Hitherto unknown mutations
may aide in the establishment of clones under the conditions
of selections. These mutations may then be selected against
as the established cell lines are propagated and, thus, they
may escape detection. Alternatively, the replicon RNA
contained in total cellular RNA may be physically different
from transcript RNAs, and this difference may be crucial
in the first steps of the initiation of replication leading to
drug resistance.
The HCV1a/PAC replicon used in our studies has one
engineered XbaI site at the 3V terminus, which generates 1a
replicon RNA with an additional 4 nucleotides at the 3V end
of the genome. It has been shown (Yi and Lemon, 2003) that
these exogenous nucleotides might reduce the replication
ability of HCV RNA but were subsequently removed during
in vivo replication. This reduction, however, was only 2- to
3-fold as compared to replicons with a wild-type 3V end (Yi
and Lemon, 2003), a result that we have confirmed in our
own studies (Liang, Lee, Paul, and Wimmer, unpublished
results), whereas the increase of colony formation with total
cellular RNA was 50-fold.
A third possibility to explain the remarkable transduction
efficiency of total RNA isolated from Huh-7 harboring
HCV1a[H77C]/PAC replicons is that the total RNA con-
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intracellular milieu favorable for the establishment of stable
cell lines under drug selection (Abe et al., 2004).
We were surprised to find five nucleotide changes in the
coding region of NS3 in variance of the published sequence
of the genotype 1a[H77C] RNA (Yanagi et al., 1997).
However, none of these changes confer beneficial effects on
transducing resistance to puromycin. Modeling of the NS3
structure from published coordinates (see Blight et al., 2003,
for references) indicated that the amino acid replacements in
1a NS3 of our replicon are all buried within the NS3
polypeptide (data not shown). Thus, a direct influence of
the amino acid substitutions on the properties of NS3 may
not be expected.
Studies with hepatitis C virus replicons have enormously
stimulated basic research on HCV. HCVoccurs in numerous
genotypes of which only genotype 1b has been subject of
intense investigations of its replication phenotypes due to
the availability of replicating replicons conferring highly
efficient resistance to neomycin selection in transfected
Huh-7 cells. Constructing replicons of genotypes other than
1b, using the exact same strategy as Lohmann et al. (1999),
may require genetic alterations of the replicons prior to
transfection (Yi and Lemon, 2004) or specially bcuredQ cells
(Blight et al., 2003; Grobler et al., 2003). An alternative
selection system such as described here will expand the
possibilities to study the multitude of HCV genotypes,
perhaps in different host cell systems. This is crucial for the
development of anti HCV drugs (Evans and Rice, 2003).Materials and methods
Cell cultures
Monolayers of human hepatoma cell line (Huh-7) were
grown in Dulbecco’s modified Eagle medium (DMEM)
(Gibco-BRL) supplemented with 2 mM l-glutamine, non-
essential amino acids, 100 units penicillin, 100 Ag strepto-
mycin, and 10% fetal bovine serum. In cells harboring HCV
replicons, 2 Ag puromycin (Sigma) per ml was added to the
growth medium. Cells were passaged two or three times per
week after treatment with 0.05% trypsin plus 0.02% EDTA
and seeded at a dilution of 1:3.
Plasmid construction
Plasmid pHCV1a/PAC (Fig. 1B) contains the sequence
of a dicistronic HCV replicon in which the 5VNTR, NS3-
NS5B sequence and the 3V NTR are derived from an in-
fectious molecular clone of the genotype 1a virus, HCV-
H77C (Yanagi et al., 1997). All amino acids and nucleotides
are referred to according to the location of their position
within the original full-length H77C HCV genome. Stand-
ard recombinant DNA technology was used to generate
this construct. All PCR fragments and final constructswere sequenced using the ABI Prism DNA sequencing
kit. In oligonucleotides, restriction sites or mutations are
underlined.
Specifically, the IRES (nucleotides 1–374) of HCV was
amplified by PCR from pCV H77C (a gift of Robert H.
Purcell) and inserted into a pSK() vector (Stratagene, La
Jolla, CA) restricted with KpnI and BamHI to generate pSK-
HCV IRES. The PAC gene was amplified by PCR using the
pPUR vector (Clontech) as template with oligonucleotide 5V-
CGCGGTACCGGATCCATGACCGAGTACAAGCC-3V
(plus-strand sequence) and oligonucleotide 5V-TGCTCTA-
GAATTCTAGGCACCGGGCTTGCGGG-3V (minus-strand
sequence). The amplified PAC fragment was cut with
BamHI and XbaI then ligated into the same site of pSK-
HCV IRES to generate pSK-HCV IRES-PAC. Next, DNA
fragments representing the EMCV IRES and HCV NS3
protein-coding sequence were fused by overlapping PCRs.
The resulting DNA was digested with EcoRI and NsiI and
then ligated with the AgeI–EcoRI fragment of pSK-HCV
IRES-PAC and the NsiI–AgeI fragment of pCV H77C to
engineer the dicistronic HCV 1a replicon, which is
composed of HCV IRES-PAC-EMCV IRES-HCV NS3-4-
5-HCV 3VNTR (Fig. 1B). The HCV 1a replicon is de-
signated HCV1a/PAC. This recombinant replicon plasmid
was later sequenced to confirm its authentic type 1a H77C
sequence except for five nucleotide changes in NS3. Two of
them [G3434C and G4721A] were silent mutations,
whereas mutations G4347A, G4522A, and A4791G led to
amino acid substitutions of A1336T, C1394Y, and R1484G,
respectively. Presently, we do not know the origin of these
mutations in our HCV1a/PAC clone.
The cell culture-adaptive mutation S2204I was introduced
into the plasmid replicon HCV1a/PAC by PCR mutagenesis
using the QuickChange PCR mutagenesis kit (Stratagene). A
subclone of pHCV(SnaBI–BspEI) of the HCV replicon in
plasmid pGEM-T was constructed and used as template
for mutagenesis. The following primers were used for
site-directed mutagenesis 5V-CCAGCTCCTCGGCTATCC-
AGCTGTCCGCTCC-3V(plus-strand sequence) and 5V-
GGAGCGGACAGCTGGATAGCCGAGGAGCTGG-
3V(minus-strand sequence). The mutant fragment was
restricted with SnaBI and BspEI and then transferred back
into the original pHCV1a/PAC replicon.
NS5B polymerase defective derivatives were generated
by changing the Gly-Asp-Asp (GDD) motif to Ala-Ala-
Gly(AAG) (Kolykhalov et al., 2000) using the Quick-
Change PCR mutagenesis kit (Stratagene) and primer pair
5V-CCATGCTCGTGTGTGCCGCCGGCTTA GTCGT-
TATCTG-3V (plus-strand sequence) and 5V-CAGATAACG-
ACTAAGCCGGCGGCA CACACGAGCATGG-3V(minus-
strand sequence).
The plasmid of the subgenomic replicon (pFK-I389neo/
NS3-3V/5.1, abbreviated as pNK5.1) was generously pro-
vided by R. Bartenschlager (Krieger et al., 2001). It is a
dicistronic construct containing the HCV 5VNTR, 16 amino
acids of the core coding region, the neo gene, and the
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NS5B, followed by the 3VNTR.
In vitro RNA transcription, RNA purification,
electroporation, and selection of
puromycin-resistant Huh-7 cells
Wild type or mutant plasmid DNAs containing H77C
sequence were linearized with XbaI and transcribed into
RNA with T7 RNA polymerase. The template DNA was
removed by twice serial digestion with RNase-free DNase I
for 30 min. The RNAwas purified with an RNeasy mini kit
(Qiagen) and was dissolved in RNase-free water. For
electroporation, subconfluent Huh-7 cells were detached
from the plate by trypsin treatment, washed 3 times with ice-
cold phosphate-buffered saline (PBS), and resuspended at
107 cells/ml in Cytomix (120 mM KCl, 0.15 mM CaCl2, 10
mM potassium phosphate, pH 7.6, 2 mM Hepes, pH 7.6, 2
mM EGTA, pH 7.6, 5 mM MgCl2) (Lohmann et al., 2001).
1–5 Ag of purified replicon RNA was mixed with 400 Al of
the cell suspensions in a cuvette with gap width of 0.4 cm
(GenePulser II System; Bio-Rad, Hercules, CA). The cell–
RNA mixture was subjected to electroporation with a Bio-
Rad Gene Pulser II at 270 V, 960 AF, and maximum
resistance. The cells were immediately transferred into 10
ml complete DMEM (supplemented with 1.25% DMSO)
and were seeded into 10-cm diameter culture dishes. After
24- to 48-h incubation, the cells were first washed with PBS
and the medium was then replaced by complete DMEM
supplemented with 1–2 Ag of puromycin (Sigma) per ml.
The medium was replaced every 2–3 days with fresh G418.
In 3–4 weeks after transfection, viable colonies were visible.
They were stained with crystal violet, or individual foci
were cloned, expanded, and stored frozen in 10% dime-
thylsulfoxide and 90% FBS in liquid nitrogen.
RNA extraction and standard one-step RT-PCR
Total cellular RNA was isolated from cell monolayers
using the TRIzol regent (Gibo-BRL) according to the
suggested protocol by the manufacturer, and further purified
with an RNeasy kit (Qiagen). Viral sequences were
amplified by the Titan one-tube RT-PCR system kit (Roche
Biochemicals) with antisense primer 5V-CGTATTCTGGTT-
GTGGGGGG-3V and sense primer 5V-GCGGGAGGTCTC-
CGTACCTGCAG-3V using the protocol suggested by the
manufacturer. The resulting 1540-bp DNA product repre-
senting nucleotides 7136–8676 within NS5B was analyzed
on a 1% agarose gel stained with ethidium bromide.
In vivo metabolic [3H] labeling assay in the presence of
actinomycin D
Cells that were passaged twice a week in the presence of
2 Ag/ml puromycin were seeded in multiple cell culture
plates and pretreated for 1 h with 5 Ag/ml actinomycin D(Sigma). Following incubation, the cells were incubated in a
culture medium containing 200 ACi of [3H]-uridine (46 Ci/
mmol) (ICN Biomedical) and 1 Ag/ml of actinomycin D. At
each time point, cells were harvested and total cellular
RNAs were isolated using the TRIzol reagent (Gibco-BRL).
[3H] uridine incorporation was determined by liquid
scintillation counting.
Western blot analysis
Total cells from 35-mm diameter plates were harvested
and lysed by a 1-min sonification in denaturing protein
sample buffer (50 mM Tris–HCl [pH 8.8], 100 mM
dithiothreitol, 0.1% bromophenol blue, 2% SDS, and 10%
glycerol). Cell lysates were subjected to SDS–polyacryla-
mide gel electrophoresis (10% acrylamide). The proteins
were transferred to a nitrocellulose (Roche) membrane by
using a SemiDry Trans Blot system (Bio-Rad), and
immunostained according to standard protocols. The HCV
proteins were specifically labeled with NS3- or NS5B-
specific monoclonal antibodies (MAb). The NS5B-specific
antibody was a kind gift of D. Moradpour.
Immunofluorescence analysis
Indirect immunofluorescence analysis of HCV NS3 or
NS5B proteins in the parental Huh-7 and replicon-contain-
ing cells was performed as described by Pietschmann et al.
(2001). In brief, cells grown as monolayers on microscope
coverslips were fixed in an ice-cold mixture of methanol
and acetone (1:1) for 10 min at 20 8C. The fixed cells were
washed with PBS and incubated for 1 h in immunofluor-
escence buffer (PBS, 3% BSA, 0.1% Triton X-100) at 4 8C.
Specific primary antibody to NS3 or NS5B protein was
added in immunofluorescence buffer, and the cells were
incubated for 1 h at room temperature. Bound primary
antibody was detected with a fluorescein isothiocyanate-
conjugated goat anti-mouse immunoglobulin. The cover-
slips were washed with PBS, mounted to a slide using
fluorescent mounting medium, and examined under a
fluorescence microscope.
Northern blot analysis
Total cellular RNA from replicon containing cells was
extracted with TRIzol reagent (Gibco-BRL) and was further
purified by using the RNeasy kit (Qiagen). Northern
analysis was performed by using the NorthernMax kit
(Ambion) according to the manufacturer’s protocol. Briefly,
5–10 Ag total cellular RNAs were separated by denaturing
agarose gel containing 2.2 M formaldehyde, vacuum trans-
ferred to a BrightStar-Plus membrane (Ambion) with
PosiBlot Pressure Blotter (Stratagene), and immobilized
by UV cross-linking (Stratagene). Hybridization was carried
out with a digoxigenin-labeled, negative-sense RNA ribo-
C. Liang et al. / Virology 333 (2005) 41–5352probe complementary to nt 59–343 of the IRES region of
HCV for 16 h at 65 8C. The membranes were washed twice
in 2 SSC–0.1% SDS for 10 min at room temperature and
three times in 0.1 SSC–0.1% SDS for a total of 45 min at
65 8C. For detection of the Dig-labeled probe, the
membranes were incubated with anti-digoxigenin-alkaline
phosphatase conjugate, reacted with CDP-star (Roche
Molecular Biochemicals), and exposed to X-ray film.
Quantitative analysis of HCV RNA
The absolute number of HCV RNA copies per cell was
determined by quantitative RT-PCR based on the Light-
Cycler sequence detection system (Roche Molecular Bio-
chemicals). Total cellular RNA isolated from a known
number of cells was subjected to a one-step real-time RT-
PCR reaction, following the protocol of a commercial kit.
Reverse transcription and amplification were performed
in 20 Al of LightCycler RNA SYBR Green I mix
containing 2.5 mM MgCl2 by using 250 ng total RNA
obtained with TRIzol reagent (Gibco-BRL) and primer 5V-
CACTCCCCTGTGAGGAACTACTGTCT-3V (plus-strand
sequence) and 5V-TGGTGCACGGTCTACGAGACCT-
CCC-3V (minus-strand sequence). This resulted in the
amplification of a 305-base pair of the 5V-NTR region
corresponding to nt 38–343. LightCycler RT-PCR was per-
formed in 1 cycle of 30 s at 55 8C for reverse transcription,
followed by 45 cycles of 5 s at 95 8C, 10 s at 55 8C, and
12 s at 72 8C with fluorescence detection at 88 8C after
each cycle. Melting-curve analysis was performed within
the range of 65–95 8C to identify the specificity of
amplification.
RT-PCR amplification and sequencing of cDNA from
replicating HCV RNAs
Total cellular RNA was extracted from replicon-contain-
ing Huh-7 cell lines by the TRIzol reagent procedure. First-
strand cDNA synthesis was carried out by using SuperScript
first-strand synthesis system for RT-PCR kit (Invitrogen)
according to the manufacturer’s suggested protocol. Briefly,
1 Ag total RNA and HCV-specific primer 5V-CATGTT-
CCTGCAGGTCCTAGGACCG-3V(minus-strand sequence)
or primer 5V-ACATGATCTGCAGAGAGGCC-3V(minus-
strand sequence) complementary to a sequence in NS5A
(nt 6506–6482) and the 3VNTR (nt 9599–9580) segments of
the genome, respectively, were used for cDNA synthesis in
a total reaction volume of 20 Al for 1 h at 42 8C. This was
followed by denaturation at 70 8C for 15 min and RNaseH
digestion to remove the RNA template. 1/10th of the
reaction mixture was used for PCR amplification with the
ExpandLong Template PCR System (Roche Biochemicals)
with 35 PCR cycles involving denaturation at 95 8C for 30
s, annealing at 55 8C for 30 s, extension at 68 8C (for 2 min
in the first 10 cycles and was increased by 10 s for each
additional cycle). The final extension reaction was at 68 8Cfor 10 min. PCR primers 5V-TGTCTTCACGCAGAA-
AGCG TCTAG-3V(plus strand sequence) and 5V-CATGTT-
CCTGCAGGTCCTAGGACCG-3V(minus-strand sequence),
or primers 5V-CAATGGATGAACCGGCTAATAGC-3V(plus
strand sequence) and 5V-ACATGATCTGCAGAGAGGCC-
3V(minus-strand sequence) were used in the PCR amplifi-
cation to amplify two overlapping segments covering almost
the complete genome of HCV1a/PAC replicon. The
amplified RT-PCR products were purified and directly
sequenced with an ABI 9600 automatic DNA sequencer.
Alternatively, these amplified cDNA products were sub-
cloned into a pGEM-T vector (Promega). Up to 30–40
clones of each fragment were sequenced to confirm the
existence of mutations.Acknowledgments
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